文献速递静脉血栓栓塞慢性静脉疾病

肿瘤合并急性静脉血栓患者需置入腔静脉滤器提示预后更差

The Need for a Vena Cava Filter in Oncological Patients with Acute Venous Thrombosis: A Marker of a Worse Prognosis.
PubMed 文献 · Ann Vasc Surg · 2019-02-23

该回顾性研究纳入247例肿瘤合并急性近端静脉血栓患者,比较需置入腔静脉滤器组(100例)与可抗凝组(147例)的生存情况。结果显示滤器组死亡风险为抗凝组的8.83倍,高于转移的OR 2.47;因临床指征置入滤器者死亡更频繁(93.2%),多因素分析调整后死亡风险高2.24倍。结论认为需置入滤器是肿瘤患者疾病严重和预后更差的标志。

要点

  • 肿瘤患者需置入腔静脉滤器提示预后更差,死亡风险为可抗凝者的8.83倍。
  • 因临床指征(如出血高风险或近期出血)置入滤器者死亡比例达93.2%。
  • 肿瘤手术前置入滤器者生存更长,可能与体能状态较好、并发症较少有关。

核心结论

  • 肿瘤患者需置入腔静脉滤器是疾病严重和预后更差的标志。

研究设计与样本

  • 回顾性分析247例肿瘤合并急性近端静脉血栓患者,比较需置入滤器组(100例)与可抗凝组(147例)的生存。

主要发现

  • 滤器组死亡风险为抗凝组的8.83倍,高于转移的OR 2.47。
  • 因临床指征置入滤器者死亡更频繁(93.2%),多因素分析调整后死亡风险高2.24倍。
  • 肿瘤手术前置入滤器者生存更长,可能与体能状态较好、临床并发症较少有关。

临床怎么用

  • 对肿瘤合并急性静脉血栓需置入腔静脉滤器者,应认识到其预后较差并加强风险评估。
  • 因临床指征(如出血高风险或近期出血)置入滤器者死亡风险更高,需密切监测。
  • 肿瘤手术前置入滤器者生存可能更长,提示筛选体能状态较好者可能获益。

局限性

  • 本研究为回顾性分析,可能存在选择偏倚。
  • 原文未报告置信区间、P值等详细统计量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active cancer is found in approximately 20% of patients diagnosed with venous thromboembolism. This condition is more prevalent in patients with advanced and metastatic cancer and is the second largest cause of death among patients with active neoplasm. Many of them have contraindication for anticoagulation and needs an inferior vena cava filter to be implanted, but a large proportion of these patients have very low survival after filter implantation. Our aim was to verify whether the need for filter implantation represents an independent indicator of poor prognosis in oncological patients and to identify subgroups with a greater survival. METHODS: This study included a retrospective analysis of 247 oncologic patients with acute proximal venous thrombosis. We compared survival between 100 consecutive patients who needed vena cava filter (FILTER group) versus a control group of 147 patients in whom anticoagulation was possible (ANTICOAGULATION group). We verified survival, cause of death, filter's indications (clinical and surgical), and factors that might lead to worse prognosis. RESULTS: Risk of death was 8.83-fold higher in the FILTER group than that in the ANTICOAGULATION group, a greater risk than the presence of metastasis (OR: 2.47). Death was significantly more frequent in patients subjected to filter implantation because of clinical indications (93.2%) such as high risk of or recent bleeding and an adjusted risk of death of 2.24-fold higher in a multivariate analysis. CONCLUSIONS: The need to implant a vena cava filter in a patient with cancer is a marker that indicates patient's disease severity and worse prognosis. Survival was longer in the subgroup of patients who underwent filter implantation before oncologic surgery, probably because of a better status performance and less clinical complications.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Leiderman DBD, Zerati AE, Vieira Mariz MP, et al. The Need for a Vena Cava Filter in Oncological Patients with Acute Venous Thrombosis: A Marker of a Worse Prognosis. Ann Vasc Surg. 2019. PMID: 30802572. doi:10.1016/j.avsg.2018.12.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。